<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486874</url>
  </required_header>
  <id_info>
    <org_study_id>283/52</org_study_id>
    <nct_id>NCT02486874</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of PoreSkin</brief_title>
  <official_title>Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PoreSkin, a human acellular dermal matrix (hADM) manufactured by Faculty of Medicine,
      Chulalongkorn University, is the first human dermal substitute developed in Thailand. It is a
      permanent dermal substitute aiming to reduce skin contracture. The objective of this study is
      to assess the safety and ability in achieving durable and cosmetic coverage of PoreSkin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The engraftment rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any local complications</measure>
    <time_frame>1 month</time_frame>
    <description>erythema, infection, fever, and rejection of the graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the final cosmetic result</measure>
    <time_frame>1 month</time_frame>
    <description>evaluated by Vancouver Scar scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PoreSkin</intervention_name>
    <description>a human acellular dermal matrix</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients

          -  18-60 years with burn scar contracture and hypertrophic scar

        Exclusion Criteria:

          -  Undergoing immunosuppressive therapy

          -  Immunocompromise host (DM, HIV infected)

          -  Evidence of malnutrition

          -  Active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Apichai Angspatt</investigator_full_name>
    <investigator_title>Apichai Angspatt</investigator_title>
  </responsible_party>
  <keyword>Human acellular dermal matrix, burns, wound healing</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

